TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06797466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D imaging technique on the PCNL
Description: Establishing a percutaneous access route for the stone is the first and most important step in PCNL surgery. Choosing the perfect route, position and direction largely depends on surgical experience and the ability to understand renal/peri-renal anatomy. In general, a good CT scan of the abdomen and pelvis and an experienced surgeon are sufficient, but this requires significant time in the learning curve. The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.
Study: NCT06794996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inaxaplin
Description: Tablets for Oral Administration.
Study: NCT06793696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse prompt
Description: Nurse prompt to complete COWS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse prompt
Description: Nurse prompt to complete COWS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse prompt
Description: Nurse prompt to complete COWS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse prompt
Description: Nurse prompt to complete COWS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider prompt
Description: Provider prompt to use EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider prompt
Description: Provider prompt to use EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider prompt
Description: Provider prompt to use EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider prompt
Description: Provider prompt to use EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient facing materials
Description: Patient materials provided at discharge from ED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient facing materials
Description: Patient materials provided at discharge from ED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient facing materials
Description: Patient materials provided at discharge from ED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient facing materials
Description: Patient materials provided at discharge from ED

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBED
Description: Original EMBED CDS
Study: NCT06796374

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin + Quercetin
Description: A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin + Quercetin
Description: A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration.
Study: NCT05806645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-guided transition of care intervention delivered through an integrated digital health strategy
Description: Patients will receive transition of care plans that are tailored to their medical profile and risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function, proteinuria and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral for high risk patients
Study: NCT06794034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: taVNS 25Hz+routine treatment, three times daily, 30 mins

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: taVNS 1Hz+routine treatment, three times daily, 30 mins
Study: NCT06797817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tributyrin
Description: Participants will receive 1 capsule per day for 12 weeks. Each capsule contains 450 mg of tributyrins. The capsules will have a gelatin coating. In the market, formulations are available with dosages ranging from 200 to 500 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of potato starch encapsulated under identical conditions to those used for the tributyrin capsules, ensuring adequate blinding of the study.
Study: NCT06797024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY231 Injection
Description: JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.
Study: NCT06796634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-plasma
Description: * Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP.~* Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations:~  * 15 W, 30W, or 45W~ * 2, 5, or 10 seconds.~* The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry.
Study: NCT06794424

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ziwig Endotest®
Description: Saliva sampling for Endometriosis diagnostic
Study: NCT06796296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Irrigation (TAI)
Description: The combination of transanal irrigation (TAI) and Loperamide involves administering Loperamide orally, with a daily dosage of 2mg. This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate sysmptoms associated with LARS
Study: NCT06792734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTM-3566
Description: Oral Solution
Study: NCT06792916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spermidine and minimally invasive non surgical tecnique
Description: minimally non surgical periodontal therapy will be performed with the adjunct of spermidine based gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peridontal therapy (minimally invasive non surgical tecnique)
Description: subgingival instrumentation will be performed according to MINST
Study: NCT06793917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Leucovorin
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Leucovorin
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
Study: NCT05849194

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POCUS examination
Description: Point of care ultrasound examination
Study: NCT05460533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
Study: NCT06793917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
Study: NCT05502081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: antiviral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: antiviral drug
Study: NCT05580965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 N pressure for 1 minute
Description: After blood collection, 20 N pressure applied for 1 minute

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 N pressure for 3 minute
Description: After blood collection, 20 N pressure applied for 3 minute
Study: NCT05140304

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT angiography
Description: OCT angiography of foveal avascular zone in diabetic retinopathy
Study: NCT04769596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK™ System
Description: The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
Study: NCT06793917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered on day 1 of each cycle at 135mg/m2
Study: NCT06796049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information pamphlet + social norm driver
Description: The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 Colorectal cancer (CRC) screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.~The information pamphlet will also contain a social norm driver that displays the sub-par screening rate the clinic compared to a collective New York State screening rate and a national screening rate goal set by the CDC.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information pamphlet
Description: The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 CRC screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.
Study: NCT06794749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: Patients received general physiotherapy in addition to action observation therapy (AOT) via telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face to face for 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients received general physiotherapy in addition to action observation therapy (AOT) via face-to-face telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face-to-face for 45 minutes.
Study: NCT05580965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 N pressure for 5 minute
Description: After blood collection, 20 N pressure applied for 5 minute
Study: NCT06797258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexHD® Pliable
Description: Acellular Dermal Matrix

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Historical Control Arm
Study: NCT06797323

Intervention type: BEHAVIORAL
Intervention: Web-Based Application for Pelvic Floor Health
Description: A user-friendly web application designed to provide educational resources, exercises, and interactive tools aimed at improving pelvic floor health in pregnant women.
Study: NCT06794619

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement with actives
Description: Dietary Supplement containing probiotic and prebiotic ingredients
Study: NCT06796517

Intervention type: DRUG
Intervention: CAR-T Therapy
Description: It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.

Intervention type: DRUG
Intervention: Bispecific antibody
Description: It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.

Intervention type: DRUG
Intervention: Antibody-Drug Conjugate
Description: It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
Study: NCT04769596

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: A Sham device will be used in the nasal cavity
Study: NCT04613713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somatocognitive physiotherapy
Description: The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions.
Study: NCT06796517

Intervention type: DRUG
Intervention: Monoclonal antibody
Description: Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.

Intervention type: DRUG
Intervention: Proteasome Inhibitor
Description: It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.

Intervention type: DRUG
Intervention: IMiD treatment
Description: Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
Study: NCT06797349

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Reference product
Description: dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second reference product
Description: dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third reference product
Description: dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Concept product
Description: Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Concept product
Description: Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Concept product
Description: Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fourth Concept product
Description: Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fifth Concept product
Description: Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sixth Concept product
Description: Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Seventh Concept product
Description: High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates
Study: NCT06789796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iparomlimab and Tuvonralimab (QL1706)
Description: 5mg/kg , every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for QL1604
Description: every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QL1604
Description: 200mg, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lacebo for Iparomlimab and Tuvonralimab (QL1706)
Description: every 3 weeks
Study: NCT06457919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinengotinib
Description: Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate 1000 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate 1000 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Enzalutamide
Description: Prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Enzalutamide
Description: Prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinengotinib
Description: The recommended phase 2 dose (RP2D).
Study: NCT06397690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Choice for HIV Prevention (MyChoice)
Description: My Choice for HIV Prevention (MyChoice) is a counselor-delivered shared decision-making approach for pregnant women considering PrEP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (control arm)
Description: Standard of care (control arm) participants will receive comprehensive education on both the advantages and limitations of each PrEP method, including guidance on potential side effects.